371 related articles for article (PubMed ID: 26617861)
21. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
Urakawa H; Nishida Y; Naruse T; Nakashima H; Ishiguro N
Clin Orthop Relat Res; 2009 Nov; 467(11):2932-8. PubMed ID: 19326179
[TBL] [Abstract][Full Text] [Related]
23. Over-expression of vitronectin correlates with impaired survival in gastric cancers.
Gong C; Hong H; Xie J; Xue Y; Huang Y; Zhang D
Medicine (Baltimore); 2021 Aug; 100(31):e26766. PubMed ID: 34397822
[TBL] [Abstract][Full Text] [Related]
24. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
25. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma.
Tian ZZ; Guo XJ; Zhao YM; Fang Y
Int J Clin Exp Pathol; 2015; 8(11):15138-42. PubMed ID: 26823857
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of neutrophil distribution in cholangiocarcinoma.
Mao ZY; Zhu GQ; Xiong M; Ren L; Bai L
World J Gastroenterol; 2015 Apr; 21(16):4961-8. PubMed ID: 25945010
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma.
Yuan D; Liu B; Liu K; Zhu G; Dai Z; Xie Y
J Surg Oncol; 2013 Sep; 108(3):157-62. PubMed ID: 23813624
[TBL] [Abstract][Full Text] [Related]
28. NPRL2 is an independent prognostic factor of osteosarcoma.
Gao Y; Wang J; Fan G
Cancer Biomark; 2012-2013; 12(1):31-6. PubMed ID: 23321467
[TBL] [Abstract][Full Text] [Related]
29. [Multivariate analysis for prognostic factors among 43 patients with osteosarcoma].
Zhang B; Pang QJ; Zhang HJ; Yuan Y
Zhongguo Gu Shang; 2011 Dec; 24(12):982-6. PubMed ID: 22276503
[TBL] [Abstract][Full Text] [Related]
30. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma.
Ma B; Li M; Zhang L; Huang M; Lei JB; Fu GH; Liu CX; Lai QW; Chen QQ; Wang YL
Tumour Biol; 2016 Apr; 37(4):4445-55. PubMed ID: 26499949
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of microRNA-26a and up-regulation of microRNA-27a contributes to aggressive progression of human osteosarcoma.
Taheriazam A; Bahador R; Karbasy SH; Jamshidi SM; Torkaman A; Yahaghi E; Shakeri M
Diagn Pathol; 2015 Sep; 10():166. PubMed ID: 26377680
[TBL] [Abstract][Full Text] [Related]
33. Vasculogenic mimicry: a new prognostic sign of human osteosarcoma.
Ren K; Yao N; Wang G; Tian L; Ma J; Shi X; Zhang L; Zhang J; Zhou X; Zhou G; Wu S; Sun X
Hum Pathol; 2014 Oct; 45(10):2120-9. PubMed ID: 25123071
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of p53 alterations in human osteosarcoma: a meta analysis.
Yao D; Cai GH; Chen J; Ling R; Wu SX; Li YP
Int J Clin Exp Pathol; 2014; 7(10):6725-33. PubMed ID: 25400752
[TBL] [Abstract][Full Text] [Related]
35. Elevated long noncoding RNA HAGLROS expression correlates with clinical progression and prognosis in osteosarcoma.
Wu PF; Dai ZT; Liu WD; Zhao ZX; Kong YH
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1428-1433. PubMed ID: 30840263
[TBL] [Abstract][Full Text] [Related]
36. Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Salom M; Montalar J; Guasp M; Marco A; Castel V
J Pediatr Hematol Oncol; 2016 Apr; 38(3):176-81. PubMed ID: 26925713
[TBL] [Abstract][Full Text] [Related]
37. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
39. Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Díaz R; Salom M; Baixauli F; Gómez J; Llavador M; Castel V
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e272-7. PubMed ID: 25374283
[TBL] [Abstract][Full Text] [Related]
40. Adverse impact of regional lymph node involvement in osteosarcoma.
Thampi S; Matthay KK; Goldsby R; DuBois SG
Eur J Cancer; 2013 Nov; 49(16):3471-6. PubMed ID: 23867123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
